Search

Hutchison China MediTech Ltd ADR

Closed

SectorHealthcare

12.36 -0.16

Overview

Share price change

24h

Current

Min

11.72

Max

12.42

Key metrics

By Trading Economics

Income

-8.9M

-8M

Sales

3.7M

139M

P/E

Sector Avg

121.8

57.366

Profit margin

-5.724

Employees

1,790

EBITDA

18M

4M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+18.52% upside

Market Stats

By TradingEconomics

Market Cap

205M

2.1B

Previous open

12.52

Previous close

12.36

News Sentiment

By Acuity

100%

0%

325 / 340 Ranking in Healthcare

Hutchison China MediTech Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

26 sie 2026, 23:56 UTC

News

Constellation Brands reported first-quarter results that beat expectations, driven by beer sales. The company also reaffirmed EPS guidance and plans a $100 million investment.

26 sie 2026, 23:31 UTC

Correlated Moves
News

The Canadian dollar weakened as Canada imposed $20 billion in tariffs on U.S. goods, contributing to negative sentiment amid ongoing U.S. inflation pressures.

26 sie 2026, 23:31 UTC

News

Interactive Brokers Group shares declined in after-market trading following a Market Perform rating from Raymond James analyst Tim DeLacey. The stock pulled back after earlier gains.

26 sie 2026, 23:26 UTC

News

Zebra Technologies is higher in after-market trading, following its TestMu Conference presentation and analyst estimates valuing shares at $399.00, above the last close of $360.52.

26 sie 2026, 23:21 UTC

News
Social Media

Oppenheimer raised Revolution Medicines' price target to $260, citing FDA approval of RASONQUE for advanced pancreatic cancer, as shares trade higher in after-market hours.

26 sie 2026, 23:16 UTC

Correlated Moves
News

Oracle Corp shares rise in after-market trading following strong fiscal fourth-quarter results, including a 93% increase in cloud-infrastructure revenue to $5.8 billion.

26 sie 2026, 23:06 UTC

News
Social Media

Amazon.com Inc announced a major expansion with Nvidia to deploy 2 million additional GPUs across AWS by 2027-2028, driving shares higher in after-market hours.

26 sie 2026, 23:06 UTC

News
Social Media

Bill Gates emphasized AI risks in a recent essay, urging stronger controls. Microsoft remains roughly flat after deciding against a cloud facility in West Virginia.

26 sie 2026, 23:06 UTC

Correlated Moves
News

Box shares are higher in after-market trading, buoyed by broader market sentiment and Salesforce's significant price movement. Management will present at Citi’s TMT Conference in 2026.

26 sie 2026, 23:06 UTC

Correlated Moves
News

Intuit Inc reported second-quarter revenue of $4.35 billion, exceeding estimates. Shares are trading higher in after-market hours following the results.

26 sie 2026, 23:02 UTC

News
Event

Ooma Inc reported fiscal Q2 revenue of $83.2 million, exceeding estimates. Shares advanced in after-market trading following raised guidance for fiscal 2027.

26 sie 2026, 23:02 UTC

News

Apple Inc shares are lower in after-market hours, reflecting a decline since Wednesday's close amid broader market pressures from PCE price index data.

26 sie 2026, 23:02 UTC

Social Media
Event
Correlated Moves
News

Veeva Systems reported strong Q2 results, raising fiscal 2027 EPS guidance to $9.21. Shares moved higher in after-hours trading following the announcements.

26 sie 2026, 23:02 UTC

News
Social Media

Okta Inc reported strong Q2 results, with revenue of $805 million and adjusted EPS of $1.05, driving shares higher in after-market trading.

26 sie 2026, 23:02 UTC

Social Media
News

Urban Outfitters shares are lower after reporting fiscal Q2 results, with adjusted earnings per share of $1.72 missing estimates of $1.73.

26 sie 2026, 23:02 UTC

Correlated Moves
News

KLA Corp shares are higher in after-market trading, supported by increased demand for process-control systems and positive trends in the semiconductor sector.

26 sie 2026, 23:02 UTC

News

Agilent Technologies reported Q3 revenue of $1.88 billion, exceeding estimates. Shares are trading higher in after-market hours following the raised full-year guidance.

26 sie 2026, 23:02 UTC

Correlated Moves
News
Social Media

Nutanix shares rose in after-hours trading following strong fourth-quarter results, with revenue of $757.1 million and adjusted EPS of $0.60 exceeding estimates.

26 sie 2026, 23:02 UTC

News
Social Media
Event

NVIDIA Corp's stock rose in after-market trading after reporting Q2 revenue of $96.22 billion, exceeding estimates, and providing strong Q3 guidance.

26 sie 2026, 23:02 UTC

News

Union Pacific and Norfolk Southern assert merger compliance with STB standards, presenting evidence of public benefits. Shares are trading higher in after-market hours.

26 sie 2026, 23:02 UTC

Correlated Moves
News

Corning Inc's shares rise in after-market trading, supported by overall market strength and a positive options market outlook. The Nasdaq 100 Index also increased.

26 sie 2026, 23:02 UTC

News
Social Media

CrowdStrike Holdings reported second-quarter revenue of $1.47 billion, exceeding expectations. The stock moved higher in after-market trading following strong guidance and record ARR.

26 sie 2026, 23:02 UTC

News
Social Media

Salesforce Inc reported second-quarter earnings of $5.90 per share, exceeding estimates. The company raised fiscal 2027 revenue guidance, driving shares higher in after-market trading.

26 sie 2026, 23:02 UTC

Correlated Moves
Social Media
News

Tenable Holdings will join the S&P SmallCap 600 effective August 31, boosting investor interest and contributing to higher after-market trading.

26 sie 2026, 23:02 UTC

News
Social Media
Event

Synopsys shares fell in after-hours trading despite strong Q3 results and raised full-year guidance, reflecting investor disappointment over limited upside potential.

26 sie 2026, 23:02 UTC

Event
News
Social Media

HP Inc. shares fell in after-hours trading following fiscal Q3 results, which showed net earnings declining to $661 million despite revenue growth to $15.7 billion.

26 sie 2026, 23:02 UTC

Correlated Moves
News

Lam Research Corp broke ground on a new R&D facility in Oregon, part of a $3 billion expansion plan, as shares rise in after-market trading.

26 sie 2026, 23:02 UTC

News

Lumen Technologies expands Multi-Cloud Gateway access to over 10 million U.S. locations. Shares are trading higher in after-market hours following the announcement.

26 sie 2026, 23:02 UTC

Correlated Moves
Social Media
News

BWX Technologies will deploy its Advanced Nuclear Reactor technology for the U.S. Army's Janus program, with shares rising in after-market trading.

26 sie 2026, 23:01 UTC

News

Verra Mobility Corp expanded its technology partnership with Hertz through a renewed five-year contract. Shares are trading higher in after-market hours.

Peer Comparison

Price change

Hutchison China MediTech Ltd ADR Forecast

Price Target

By TipRanks

18.52% upside

12 Months Forecast

Average 14.53 USD  18.52%

High 16 USD

Low 13.6 USD

Based on 3 Wall Street analysts offering 12 month price targets forHutchison China MediTech Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

3 ratings

1

Buy

2

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
help-icon Live chat